ANTITUMOR COMBINATIONS CONTAINING TAXANE DERIVATIVES
The disclosure relates to pharmaceutical combinations comprising acetylcyclopropyl docetaxel and a monoclonal antibody against ErbB2, and to methods of use thereof.
1 . A pharmaceutical combination comprising the compound of formula I:
and a monoclonal antibody against ErbB2.
2 . The pharmaceutical combination according to claim 1 , further comprising growth factors of the haematopoietic type.
3 . The pharmaceutical combination according to claim 1 , wherein the combination has therapeutic synergy.
4 . The pharmaceutical combination according to claim 1 for the treatment of cancer.
5 . The pharmaceutical combination according to claim 1 for the treatment of breast cancer, ovarian cancer, lung cancer, melanoma and leukemia.
6 . The pharmaceutical combination according to claim 1 for the treatment of breast cancer.
7 . The pharmaceutical combination according to claim 1 for the treatment of a cancer resistant to taxoids.
8 . The pharmaceutical combination according to claim 1 for the treatment of breast cancer resistant to taxoids.
9 . The pharmaceutical combination according to claim 1 wherein the monoclonal antibody against ErbB2 is trastuzumab.
10 . A method of treating cancer in a patient comprising administering to said patent a therapeutically effective amount of a compound of formula I:
in combination with a monoclonal antibody against ErbB2.
11 . The method according to claim 10 wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, lung cancer, melanoma and leukemia.
12 . The method according to claim 10 wherein the cancer is resistant to taxoids.
13 . The method according to claim 10 wherein the cancer is breast cancer that is resistant to taxoids.
14 . The method according to claim 10 wherein the cancer is resistant to paclitaxel or docetaxel.
15 . The method according to claim 10 wherein the cancer is breast cancer that is resistant to paclitaxel or docetaxel.
16 . The method according to claim 10 wherein the monoclonal antibody against ErbB2 is trastuzumab.
17 . The method according to claim 10 wherein the compound of formula I is administered simultaneously with the monoclonal antibody against ErbB2.
18 . The method according to claim 10 wherein the compound of formula I is administered semi-simultaneously with the monoclonal antibody against ErbB2.
19 . The method according to claim 10 wherein the compound of formula I is administered separately over time from the monoclonal antibody against ErbB2.
20 . A method of treating cancer in a patient comprising administering to said patient a synergistically effective amount of a combination comprising a compound of formula I:
and a monoclonal antibody against ErbB2.
21 . A method of treating cancer in a patient comprising administering to said patient an effective amount of a synergistic combination comprising a compound of formula I:
and a monoclonal antibody against ErbB2.